SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs and Pharmaceuticals informs about newspaper advertisements

19 Jun 2026 Evaluate

Pursuant to Regulation 30 read with Schedule III of Part A of Para A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals has informed that it enclosed copies of the newspaper advertisements published in Business Standard (English) and Business Standard (Hindi) on June 19, 2026, in connection with 22nd Annual General Meeting of the company scheduled to be held on Friday, July 10, 2026 at 11:00 am (IST), through Video Conferencing (‘VC’)/ Other Audio-Visual Means (‘OAVM’). A copy of this disclosure is being updated on website of the Company at www.akums.in.

The above information is a part of company’s filings submitted to BSE.

Akums Drugs & Pharma Share Price

626.20 -10.85 (-1.70%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: